Under the terms of the five year contract Emergent must develop the device as well as demonstrate consistency in manufacturing, functionality and usability of the final device and undertake regulatory activities required to obtain FDA approval for use of the auto-injector in a bioterrorism incident.
“Ease of use and rapid delivery of antidotes are critical features of auto-injectors that are intended to mitigate the health effects of nerve agent exposure,” Adam Havey, executive vice president of Business Operations at Emergent, said. “Emergent’s device seeks to satisfy the requirements of the Department of Defense (DOD) for a novel auto-injector platform technology, and we look forward to collaborating with our development partners to meet the DOD’s needs.”

  • Follow us on Twitter
  • Subscribe to CBRNe news

View articles by date